Literature DB >> 9557663

The class II membrane glycoprotein G of bovine respiratory syncytial virus, expressed from a synthetic open reading frame, is incorporated into virions of recombinant bovine herpesvirus 1.

G Kühnle1, A Heinze, J Schmitt, K Giesow, G Taylor, I Morrison, F A Rijsewijk, J T van Oirschot, G M Keil.   

Abstract

The bovine herpesvirus 1 (BHV-1) recombinants BHV-1/eG(ori) and BHV-1/eG(syn) were isolated after insertion of expression cassettes which contained either a genomic RNA-derived cDNA fragment (BHV-1/eG(ori)) or a modified, chemically synthesized open reading frame (ORF) (BHV-1/eG(syn)), which both encode the attachment glycoprotein G of bovine respiratory syncytial virus (BRSV), a class II membrane glycoprotein. Northern blot analyses and nuclear runoff transcription experiments indicated that transcripts encompassing the authentic BRSV G ORF were unstable in the nucleus of BHV-1/eG(ori)-infected cells. In contrast, high levels of BRSV G RNA were detected in BHV-1/eG(syn)-infected cells. Immunoblots showed that the BHV-1/eG(syn)-expressed BRSV G glycoprotein contains N- and O-linked carbohydrates and that it is incorporated into the membrane of infected cells and into the envelope of BHV-1/eG(syn) virions. The latter was also demonstrated by neutralization of BHV-1/eG(syn) infectivity by monoclonal antibodies or polyclonal anti-BRSV G antisera and complement. Our results show that expression of the BRSV G glycoprotein by BHV-1 was dependent on the modification of the BRSV G ORF and indicate that incorporation of class II membrane glycoproteins into BHV-1 virions does not necessarily require BHV-1-specific signals. This raises the possibility of targeting heterologous polypeptides to the viral envelope, which might enable the construction of BHV-1 recombinants with new biological properties and the development of improved BHV-1-based live and inactivated vector vaccines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9557663      PMCID: PMC109603          DOI: 10.1128/JVI.72.5.3804-3811.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Bovine herpesvirus 1 U(s) open reading frame 4 encodes a glycoproteoglycan.

Authors:  G M Keil; T Engelhardt; A Karger; M Enz
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

2.  Antigenically distinct G glycoproteins of BRSV strains share a high degree of genetic homogeneity.

Authors:  J M Furze; S R Roberts; G W Wertz; G Taylor
Journal:  Virology       Date:  1997-04-28       Impact factor: 3.616

3.  Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene.

Authors:  M E Greenberg; E B Ziff
Journal:  Nature       Date:  1984 Oct 4-10       Impact factor: 49.962

4.  Cloning and cleavage site mapping of DNA from bovine herpesvirus 1 (Cooper strain).

Authors:  J E Mayfield; P J Good; H J VanOort; A R Campbell; D E Reed
Journal:  J Virol       Date:  1983-07       Impact factor: 5.103

5.  A catalogue of splice junction sequences.

Authors:  S M Mount
Journal:  Nucleic Acids Res       Date:  1982-01-22       Impact factor: 16.971

6.  Expression of bovine interleukin-1 beta in a bovine herpesvirus-1 vector: in vitro analysis.

Authors:  C Raggo; D R Fitzpatrick; L A Babiuk; X Liang
Journal:  Virology       Date:  1996-07-01       Impact factor: 3.616

7.  Inactivated bovine herpesvirus 1 induces apoptotic cell death of mitogen-stimulated bovine peripheral blood mononuclear cells.

Authors:  E Hanon; A Vanderplasschen; S Lyaku; G Keil; M Denis; P P Pastoret
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

8.  Construction of bovine herpesvirus-1 (BHV-1) recombinants which express pseudorabies virus (PRV) glycoproteins gB, gC, gD, and gE.

Authors:  H Otsuka; X Xuan
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

9.  Identification and characterization of the bovine herpesvirus 1 UL7 gene and gene product which are not essential for virus replication in cell culture.

Authors:  J Schmitt; G M Keil
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

10.  A glycoprotein E deletion mutant of bovine herpesvirus 1 is avirulent in calves.

Authors:  F A van Engelenburg; M J Kaashoek; F A Rijsewijk; L van den Burg; A Moerman; A L Gielkens; J T van Oirschot
Journal:  J Gen Virol       Date:  1994-09       Impact factor: 3.891

View more
  6 in total

Review 1.  BHV-1: new molecular approaches to control a common and widespread infection.

Authors:  L Turin; S Russo; G Poli
Journal:  Mol Med       Date:  1999-05       Impact factor: 6.354

2.  Expression of the genomic form of the bovine viral diarrhea virus E2 ORF in a bovine herpesvirus-1 vector.

Authors:  Lingshu Wang; J Charles Whitbeck; William C Lawrence; Denys V Volgin; Leonard J Bello
Journal:  Virus Genes       Date:  2003-08       Impact factor: 2.332

3.  A hepadnavirus regulatory element enhances expression of a type 2 bovine viral diarrhea virus E2 protein from a bovine herpesvirus 1 vector.

Authors:  Lingshu Wang; Sreekumar Menon; Steven R Bolin; Leonard J Bello
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

4.  Construction and manipulation of an infectious clone of the bovine herpesvirus 1 genome maintained as a bacterial artificial chromosome.

Authors:  Timothy J Mahony; Fiona M McCarthy; Jennifer L Gravel; Lani West; Peter L Young
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

5.  Recombinant bovine adenovirus-3 co-expressing bovine respiratory syncytial virus glycoprotein G and truncated glycoprotein gD of bovine herpesvirus-1 induce immune responses in cotton rats.

Authors:  Robert Brownlie; Pankaj Kumar; Lorne A Babiuk; Suresh Kumar Tikoo
Journal:  Mol Biotechnol       Date:  2015-01       Impact factor: 2.860

Review 6.  Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems.

Authors:  Alejandro Brun; Emmanuel Albina; Tom Barret; David A G Chapman; Markus Czub; Linda K Dixon; Günther M Keil; Bernard Klonjkowski; Marie-Frédérique Le Potier; Geneviève Libeau; Javier Ortego; Jennifer Richardson; Haru-H Takamatsu
Journal:  Vaccine       Date:  2008-12-02       Impact factor: 3.641

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.